ACT,NVS -

. Currency in USD
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Training cells to fight cancer
    CNBC Videos18 days ago

    Training cells to fight cancer

    In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.

  • Historic treatment, historic price
    CNBC Videos18 days ago

    Historic treatment, historic price

    Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i...

  • American City Business Journals13 hours ago

    Drugmaker Novartis to close 450-employee Sandoz plant in Broomfield

    Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result. The Sandoz facility has been in Broomfield for 42 years. Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said.

  • Let's Talk About CAR-T
    GuruFocus.com20 hours ago

    Let's Talk About CAR-T

    A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market

  • Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
    Investor's Business Dailyyesterday

    Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field

    Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.

  • Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy
    InvestorPlace4 days ago

    Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy

    Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.

  • Reuters6 days ago

    Novartis decides not to sell Roche stake chairman tells newspaper

    Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung. "We said we would review whether it makes sense to sell the stake," Reinhardt told the newspaper. In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks.

  • Forbes6 days ago

    Here Come More Gene Therapies -- And More Pricing Debates

    Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.

  • 4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
    Zacks12 days ago

    4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

    The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

  • Market Realist12 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
    Zacks14 days ago

    FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta

    Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta

  • Barrons.com15 days ago

    [$$] Lilly Faces Off With Pfizer, Novartis

    Credit Suisse Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy. Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly. Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease.

  • CNBC18 days ago

    Two patients show the promise of a historic treatment, with an equally historic price tag

    Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.

  • Ligand's Captisol Deals Set to Drive Growth in the Long Run
    Zacks18 days ago

    Ligand's Captisol Deals Set to Drive Growth in the Long Run

    Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.

  • Forbes18 days ago

    Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet

    Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model.

  • Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'
    Investor's Business Daily19 days ago

    Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical'

    Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.

  • Why Advanced Accelerator Application SA Stock Jumped Higher Today
    Motley Fool19 days ago

    Why Advanced Accelerator Application SA Stock Jumped Higher Today

    An acquisition rumor has the radiopharmaceutical company's shares on the rise.

  • Reuters19 days ago

    Novartis forges UC Berkeley pact, sees drug hopefuls in 3 years

    Novartis's research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines. Novartis announced the Novartis-Berkeley Center for Proteomics and Chemistry Technologies on Thursday. Basel-based Novartis hopes Berkeley scientists including Daniel Nomura, the professor who runs the lab, will speed its search for the Achilles' heels of hard-to-treat diseases.

  • Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA
    Bloomberg20 days ago

    Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA

    Novartis AG is considering a deal for radiopharmaceutical company Advanced Accelerator Applications SA as the giant Swiss drugmaker seeks acquisitions to boost growth, according to people familiar with ...

  • 3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day
    Zacks21 days ago

    3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

    With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

  • Oddly, Juno Therapeutics Is Jumping 11.3% Today
    Motley Fool25 days ago

    Oddly, Juno Therapeutics Is Jumping 11.3% Today

    Optimism that it can develop CAR-T cancer drugs that are better than its competitors' is trumping news that the company is diluting investors by selling more shares.

  • Market Realist25 days ago

    How Is Novartis’s Subsidiary Sandoz Positioned after 1H17?

    In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis.

  • Market Realist25 days ago

    Gilenya and Entresto Could Keep Boosting Novartis’s Revenue Growth

    In 1H17, Novartis’s (NVS) Gilenya reported revenues of around $1.6 billion, which reflected ~3% growth on a year-over-year (or YoY) basis.

  • The Wall Street Journal25 days ago

    [$$] Alnylam's New Medicine To Enter Pricing Debate

    Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.